Clinical Trial Detail

NCT ID NCT02971761
Title Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

triple-receptor negative breast cancer

Therapies

enobosarm + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.